ECUR-506
Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Key Facts
About iECURE
iECURE is a private, pre-revenue biotech leveraging a disruptive in vivo gene insertion platform to develop potentially curative treatments for rare liver disorders. The company's core strategy is built on an exclusive, foundational collaboration with the University of Pennsylvania's Gene Therapy Program (GTP), providing deep translational R&D expertise. Its most advanced asset, ECUR-506 for OTC deficiency, has received FDA RMAT designation and is in clinical trials, positioning iECURE as a notable player in next-generation gene editing.
View full company profileAbout Precision BioSciences
Precision BioSciences is a clinical-stage biotech leveraging its proprietary ARCUS genome editing platform to develop potentially curative in vivo therapies for genetic diseases. The company has advanced two wholly-owned programs into Phase 1/2 trials: PBGENE-HBV for chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy, both supported by key regulatory designations. Its strategy combines advancing these core assets with strategic partnerships to validate and fund the ARCUS platform, positioning it in the competitive but high-potential gene editing landscape.
View full company profile